GlassScriptPhysician profile
Ronald W Johns
NPI 1750376703
$2,753.00
in general payments reported to CMS, 2019-2025
28 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $287 · 2021: $621 · 2022: $188 · 2023: $384 · 2024: $439 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $539.16 | 2019-2025 | Otezla, Repatha, Otezla |
| Medtronic, INC. | $344.87 | 2021-2025 | Intellis Adaptivestim, Percept PC Brainsense |
| Lilly USA, LLC | $304.98 | 2019-2021 | |
| Novo Nordisk INC | $196.31 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Harmony Biosciences LLC | $178.49 | 2023-2025 | Wakix |
| Horizon Therapeutics Plc | $125.00 | 2023 | Krystexxa |
| Genzyme Corporation | $124.14 | 2024 | |
| Astellas Pharma US INC | $94.94 | 2019-2023 | Veozah |
| Pfizer INC. | $94.85 | 2020-2024 | |
| Inari Medical, INC. | $88.08 | 2021 | |
| Glaxosmithkline, LLC. | $82.55 | 2019-2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $76.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $75.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $53.90 | 2023-2025 | Airsupra, Fasenra |
| Allergan, INC. | $45.54 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $45.09 | 2020-2021 | |
| Circassia INC. | $39.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.03 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $34.94 | 2021 | |
| Genentech USA, INC. | $30.62 | 2019 | |
| Collegium Pharmaceutical, INC. | $24.54 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.73 | 2019 | |
| Abbott Laboratories | $19.80 | 2024 | Proclaim |
| Antares Pharma, INC. | $16.23 | 2025 | Xyosted |
| Abbvie INC. | $14.41 | 2021 | |
| Inspire Medical Systems, INC. | $14.06 | 2023 | Inspire |
| Ironshore Pharmaceuticals INC. | $13.34 | 2024 | |
| Alexion Pharmaceuticals, INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.